These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33628850)

  • 1. Application of Bionanomaterials in Tumor Immune Microenvironment Therapy.
    Wang J; Bao Y; Yao Y
    J Immunol Res; 2021; 2021():6663035. PubMed ID: 33628850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy.
    Leone RD; Powell JD
    Cancer Immunol Res; 2021 Mar; 9(3):255-260. PubMed ID: 33648947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Immune Microenvironment and Its Related miRNAs in Tumor Progression.
    Xing Y; Ruan G; Ni H; Qin H; Chen S; Gu X; Shang J; Zhou Y; Tao X; Zheng L
    Front Immunol; 2021; 12():624725. PubMed ID: 34084160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy.
    Huo S; Liu L; Li Q; Wang J
    Discov Med; 2020; 30(161):119-128. PubMed ID: 33593480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells.
    Ramachandran M; Dimberg A; Essand M
    Semin Cancer Biol; 2017 Aug; 45():23-35. PubMed ID: 28257957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomaterial-assisted targeted modulation of immune cells in cancer treatment.
    Wang H; Mooney DJ
    Nat Mater; 2018 Sep; 17(9):761-772. PubMed ID: 30104668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies.
    Liu Y; Guo J; Huang L
    Theranostics; 2020; 10(7):3099-3117. PubMed ID: 32194857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.
    Clappaert EJ; Murgaski A; Van Damme H; Kiss M; Laoui D
    Front Immunol; 2018; 9():2250. PubMed ID: 30349530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
    Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
    Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
    Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
    Front Immunol; 2018; 9():1288. PubMed ID: 29915603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversing T-cell Dysfunction and Exhaustion in Cancer.
    Zarour HM
    Clin Cancer Res; 2016 Apr; 22(8):1856-64. PubMed ID: 27084739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Opportunities and Challenges in Cancer Immunotherapy.
    Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I
    Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unzippable Siamese Nanoparticles for Programmed Two-Stage Cancer Immunotherapy.
    Long M; Zhou Y; Guo D; Zhu Q; Liang H; Ji X; Chen N; Song H
    Adv Mater; 2024 Aug; 36(31):e2402456. PubMed ID: 38810924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
    Vo MC; Yang S; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Lee JJ
    Front Immunol; 2018; 9():1798. PubMed ID: 30123221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy.
    Yin Z; Bai L; Li W; Zeng T; Tian H; Cui J
    J Exp Clin Cancer Res; 2019 Sep; 38(1):403. PubMed ID: 31519198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy.
    Kuai R; Yuan W; Son S; Nam J; Xu Y; Fan Y; Schwendeman A; Moon JJ
    Sci Adv; 2018 Apr; 4(4):eaao1736. PubMed ID: 29675465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosomes as mediators of immune regulation and immunotherapy in cancer.
    Kugeratski FG; Kalluri R
    FEBS J; 2021 Jan; 288(1):10-35. PubMed ID: 32910536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodegradable Hollow Mesoporous Silica Nanoparticles for Regulating Tumor Microenvironment and Enhancing Antitumor Efficiency.
    Kong M; Tang J; Qiao Q; Wu T; Qi Y; Tan S; Gao X; Zhang Z
    Theranostics; 2017; 7(13):3276-3292. PubMed ID: 28900509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving synergistic combinations of targeted immunotherapies to combat cancer.
    Melero I; Berman DM; Aznar MA; Korman AJ; Pérez Gracia JL; Haanen J
    Nat Rev Cancer; 2015 Aug; 15(8):457-72. PubMed ID: 26205340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.